KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Share-based Compensation (2016 - 2025)

Biogen (BIIB) has 17 years of Share-based Compensation data on record, last reported at $59.6 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 20.64% year-over-year to $59.6 million; the TTM value through Dec 2025 reached $290.8 million, changed 0.14%, while the annual FY2025 figure was $290.8 million, 0.14% changed from the prior year.
  • Share-based Compensation reached $59.6 million in Q4 2025 per BIIB's latest filing, down from $75.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $81.0 million in Q1 2025 and bottomed at $54.1 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $66.9 million, with a median of $68.8 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: skyrocketed 66.27% in 2021, then fell 20.64% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $58.8 million in 2021, then rose by 14.29% to $67.2 million in 2022, then decreased by 18.3% to $54.9 million in 2023, then surged by 36.79% to $75.1 million in 2024, then decreased by 20.64% to $59.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $59.6 million in Q4 2025, $75.3 million in Q3 2025, and $74.9 million in Q2 2025.